Skip to main content
Log in

Enhancement of delayed cutaneous hypersensitivity in untreated cancer patients given a short-term oral treatment with C 1821

  • Short Communication
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

C 1821 is a purified glycoprotein extract of Klebsiella pneumoniae serotype 2 with immunomodulating properties in animals (in vivo and in vitro) and in humans (in vitro). The compound is devoid of any apparent toxicity when given orally. The aim of the present work was to evaluate the effects of a short term oral administration of C 1821 on delayed cutaneous hypersensitivity to recall antigens in untreated cancer patients (mostly lymphomas). Consecutive patients were alternately allocated to receive C 1821 or placebo for 14 days. C 1821 restored and significanty (P<0.02) enhanced skin reactions, as shown using the Multitest system.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Brugmans J, Schermans V, De Cock W, Thienpont D, Janssen P, Verhaegen H, Van Nimmen L, Louwagie AC, Stevens E (1973) Restoration of host defence mechanisms in man by levamisole. Life Sci 13:1499

    Google Scholar 

  2. Catalona WJ, Sample WF, Chrétien PB (1973) Lymphocyte reactivity in cancer patients: Correlation with tumor histology and clinical stage. Cancer 31:65

    CAS  PubMed  Google Scholar 

  3. Eilber FR, Nizze JA, Morton DL (1975) Sequential evaluation of general immune competence in cancer patients: Correlation with clinical course. Cancer 35:660

    Google Scholar 

  4. Griscelli C, Grospierre B, Montreuil J, Fournet B, Bruvier G, Lang JM, Buret JP, Zalisz R, Edelstein R (1981) Immunomodulation by glycoprotein fractions isolated from Klebsiella pneumoniae. Paper presented at the International Symposium on Immunomodulation by Microbial Products and Related Synthetic Sompounds, Osaka, Japan, 1981 (proceedings in press)

  5. Hirshaut Y, Pinsky CM, Marquardt H, Oettgen HF (1973) Effects of levamisole on delayed hypersensitivity reactions in cancer patients. Proc Am Assoc Cancer Res 14:109

    Google Scholar 

  6. Hirshaut Y, Pinsky CM, Frydecka I, Wanebo HM, Passe S, Mike V, Oettgen HF (1980) Effect of short-term levamisole therapy on delayed hypersensitivity. Cancer 45:362

    Google Scholar 

  7. Hogan TF, Borden EC, Freeberg BL, Vieau J, Hsieh FY, Crowley J (1980) Enhancement in recall antigen responses by frequent, repetitive skin testing with Candida, mumps, and streptokinase-streptodornase in 38 normal adults. Cancer Immunol Immunother 10:27

    Google Scholar 

  8. Keystone EC, Demerieux P, Gladman D, Poplonski L, Piper S, Buchanan R (1980) Enhanced delayed hypersensitivity skin test reactivity with serial testing in healthy volunteers. Clin Exp Immunol 40:202

    Google Scholar 

  9. Kniker WT, Anderson MD, Roumiantzeff M (1979) The Multi-test system: a standardized approach to evaluation of delayed hypersensitivity and cell-mediated immunity. Ann Allergy 43:73

    Google Scholar 

  10. Lee YTN, Sparks FC, Eilber FR, Morton DL (1975) Delayed cutaneous hypersensitivity and peripheral lymphocyte counts in patients with advanced cancer. Cancer 35:748

    Google Scholar 

  11. Lichtenstein A, Zighelboim J, Dorey F, Brossman S, Fahey JL (1980) Comparison of immune derangements in patients with different malignancies. Cancer 45:2090

    Google Scholar 

  12. Mujacic H, Deskovic M, Malenica B, Bistrovic M, Nola P, Krusic J (1980) The significance of tuberculin immunity testing in cancer patients. Cell Mol Biol 26:111

    Google Scholar 

  13. Pinsky CM, Wanebo H, Mike V, Oettgen H (1976) Delayed cutaneous hypersensitivity reactions and prognosis in patients with cancer. Ann NY Acad Sci 276:407

    Google Scholar 

  14. Serrou B, Cupissol D, Flad H, Goutner A, Lang JM, Spirzglas H, Plagne R, Beltzer M, Chollet P, Muthé G (1980) Phase I evaluation of Bestatin in patients bearing advanced solid tumors. (Abstract) Int J Immunopharmacol 2:168

    Google Scholar 

  15. Teasdale C, Hughes LE, Whitehead RH, Newcombe RG (1979) Factors affecting pretreatment immune competence in cancer patients. I. The effects of age, sex, and ill health. II. The corrected effects of malignant disease. Cancer Immunol Immunother 6:89

    Google Scholar 

  16. Tripodi D, Parks LC, Brugmans J (1973) Drug-induced restoration of cutaneous delayed hypersensitivity in anergic patients with cancer. N Engl J Med 289:354

    Google Scholar 

  17. Webster DJT, Hughes LE (1975) Levamisole. Lancet I:389

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lang, JM., Giron, C., Aleksijevic, A. et al. Enhancement of delayed cutaneous hypersensitivity in untreated cancer patients given a short-term oral treatment with C 1821. Cancer Immunol Immunother 14, 59–60 (1982). https://doi.org/10.1007/BF00199434

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00199434

Keywords

Navigation